Skip to Content
Merck
All Photos(1)

Key Documents

319R-2

Sigma-Aldrich

Cytokeratin 19 (EP72) Rabbit Monoclonal Primary Antibody

Synonym(s):

40-kDa keratin intermediate filament, CK-19, CK19, K19, K1CS, KRT 19, cytokeratin-19, keratin 19, type 1, keratin, type 1, 40-kd, keratin-19

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP72, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (319R-24)
vial of 0.1 mL concentrate Research Use Only (319R-24-RUO)
vial of 0.5 mL concentrate (319R-25)
vial of 1.0 mL concentrate (319R-26)
vial of 1.0 mL concentrate Research Use Only (319R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (319R-27-RUO)
vial of 1.0 mL predilute ready-to-use (319R-27)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (319R-28-RUO)
vial of 7.0 mL predilute ready-to-use (319R-28)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200 (concentrated)

isotype

IgG

control

bladder, colon, colon carcinoma, thyroid carcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... KRT19(3880)

Related Categories

General description

Anti-cytokeratin 19 reacts with epithelia and epithelial malignancies including carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Anti-cytokeratin 19 is very useful in differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma, especially in a combination of cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep Par-1 and TTF1. Another useful application is the identification of thyroid papillary carcinoma.

Quality

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

Linkage

Cytokeratin 19 Positive Control Slides, Product No. 319S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Predilute: diluted in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Concentrate: diluted in Phosphate Buffered Saline, pH 7.2, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Juan Rosai
Tumori, 89(5), 517-519 (2004-02-12)
Immunohistochemical markers of thyroid tumors can be divided into two major categories: those related to the cell types and those related to the type of pathology. The most important markers in the first category are thyroglobulin and TTF-1 for follicular
Richa Jain et al.
Applied immunohistochemistry & molecular morphology : AIMM, 18(1), 9-15 (2009-12-04)
Cytokeratin immunostaining forms the bedrock of the immunohistochemical evaluation of tumors. Cytokeratin 19 (CK19) belongs to a family of keratins, which are normally expressed in the lining of the gastroenteropancreatic and hepatobiliary tracts. CK19 immunohistochemistry has been used successfully in
Leandro Luongo de Matos et al.
Diagnostic pathology, 7, 97-97 (2012-08-15)
To distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service